Nisha Pandey

Health and Me

Eli Lilly Can Continue Zepbound Ads Despite Novo Nordisk’s Claims Over Weight-Loss Drug Comparisons

There’s a new update in Novo Nordisk Vs Eli Lilly lawsuit over weight loss ads. On Monday, a US judge ruled in favour of Eli Lilly, rejecting Novo Nordisk’s request to block the Zepbound maker’s advertisements. The Danish drugmaker claimed that those advertisements were false and misleading, which affected markets with tens of billions of dollars of annual sales.

<h2>Eli Lilly Can Continue Running Ads Amid Novo Nordisk’s Lawsuit</h2>

US District Judge Zahid Quraishi in Trenton, New Jersey, said that <a href="https://www.healthandme.com/parenting/who-cautions-against-glp-1s-as-first-line-treatment-for-childhood-obesity-prioritises-lifestyle-changes-article-156290345" data-type="tilCustomLink">Novo Nordisk</a> must not receive a preliminary injunction, as they have failed to prove that Eli Lilly's ads threatened their sales, marred its goodwill, or caused irreparable damage to clinical reputation.

Talking about Novo Nordisk's claim of irreparable harm, Quraishi said they were "inadequate to warrant ⁠the extraordinary relief it seeks." 

Quraishi also said that Novo Nordisk's case is "less than persuasive" based on a "very preliminary record.” Not considering these merits, the judge passed the ruling after a two-day hearing in August.

In his 25-page decision, Quraishi said that even though Novo Nordisk's witnesses were reliable, Eli Lilly's ads had a negligible market impact between April and July. The judge also said that Novo Nordisk's business remained stable.

The judge also said that monetary compensation could help Novo Nordisk if it faces any "nontrivial harm" due to absence of ⁠injunction.

Novo Nordisk had reported combined sales of about $32 billion for obesity medicines and <a href="https://www.healthandme.com/health-wellness/is-ozempic-face-influencing-the-beauty-industry-global-cosmetic-brand-highlights-a-new-trend-amid-glp-1-boom-article-156390682" data-type="tilCustomLink">Ozempic</a> in 2025, according to the court papers. The drugmaker intends to regain market share in the United States for its injectable obesity drugs, a market that could exceed $100 billion by the end of the decade.

According to Reuters, Novo Nordisk said, “While we are disappointed with the court’s decision, today's ruling did not decide the question of whether Lilly's advertising is false and misleading, and this litigation is still ongoing. Everyone deserves clear, accurate and up-to-date information when making decisions about their health.”

Denying any wrongdoing, Eli Lilly said it welcomed the court’s decision.

Also read: <a href="https://www.healthandme.com/health-news/glp-1-drugs-ozempic-zepbound-use-rises-24-fold-among-american-women-after-childbirth-article-156260422" data-type="tilCustomLink">GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth</a>

In July, Danish drugmaker Novo Nordisk had filed a lawsuit against Eli Lilly in the US District Court in New Jersey, alleging the company violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug <a href="https://www.healthandme.com/health-news/glp-1-drug-mounjaro-zepbound-ingredient-recalled-in-us-over-sterility-concerns-article-156376227" data-type="tilCustomLink">Zepbound</a> and diabetes treatment Mounjaro, according to media reports.

Alleging that Eli Lilly’s ads used outdated comparisons,Novo claims Lilly's advertisements:

<ul><li>Compared the highest approved doses of Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic.</li><li>Omitted data on the newer 7.2 mg dose of Wegovy, which, as per Novo, delivers greater weight loss.</li><li>Relied on older clinical trial data that no longer reflects current approved dosing.</li></ul>

Eli Lilly rejected the allegations, saying its advertisements accurately reflect findings from its SURMOUNT-5 clinical trial. According to the company:

<ul><li>The study, completed in 2024, compared 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg doses of Wegovy.</li><li>Novo's 7.2 mg Wegovy received US FDA approval only in March 2026, after the trial had concluded.</li></ul>

FSSAI Supplement Crackdown: Expert Exposes Fake Health Claims & Risks

Also read: <a href="https://www.healthandme.com/health-wellness/eli-lillys-experimental-glp-1-pill-shows-promising-weight-loss-article-151459744" data-type="tilCustomLink">Eli Lilly's Experimental GLP-1 Pill Shows Promising Weight Loss</a>

In December 2025, the World Health Organization (WHO) issued its first guideline on the use of GLP-1 therapies for obesity, describing the condition as a chronic, relapsing disease affecting more than 1 billion people worldwide. 

It recommends GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women. Treatment should be combined with structured lifestyle interventions, including a healthy diet, regular physical activity, and behavioral support to improve outcomes.

Dr. Vivek Bindal, Principal Director &amp; Head at Max Institute of Minimal Access, Bariatric &amp; Robotic Surgery, said, “Newer anti-obesity medicines, including GLP-1-based and related therapies, have significantly expanded the options available to patients. They can support meaningful weight loss and improve metabolic health when combined with appropriate nutrition, physical activity and behavioural support.”

Health Conditions A-Z

health

eli-lilly-can-continue-zepbound-ads-despite-novo-nordisks-claims-over-weight-loss-drug-comparisons

novo

Novo Nordisk Eli Lilly lawsuit

novo nordisk

lilly

eli lilly

zahid quraishi

wegovy

mounjaro

us fda

mercks-experimental-drug-extends-survival-by-nearly-7-months-in-endometrial-cancer-trial

Merck’s Experimental Drug Extends Survival By Nearly 7 Months In Endometrial Cancer Trial

children-who-eat-more-ultra-processed-foods-may-have-stronger-brain-responses-that-increase-cravings

Children Who Eat More Ultra-Processed Foods May Have Stronger Brain Responses That Increase Cravings

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

There’s a new update in Novo Nordisk Vs Eli Lilly lawsuit over weight loss ads. On Monday, a US judge ruled in favour of Eli Lilly, rejecting Novo Nordisk’s request to block the Zepbound maker’s advertisements. The Danish drugmaker claimed that those advertisements were false and misleading, which affected markets with tens of billions of dollars of annual sales.Eli Lilly Can Continue Running Ads Amid Novo Nordisk’s LawsuitUS District Judge Zahid Quraishi in Trenton, New Jersey, said that Novo Nordisk must not receive a preliminary injunction, as they have failed to prove that Eli Lilly's ads threatened their sales, marred its goodwill, or caused irreparable damage to clinical reputation.Talking about Novo Nordisk's claim of irreparable harm, Quraishi said they were "inadequate to warrant ⁠the extraordinary relief it seeks." Quraishi also said that Novo Nordisk's case is "less than persuasive" based on a "very preliminary record.” Not considering these merits, the judge passed the ruling after a two-day hearing in August.In his 25-page decision, Quraishi said that even though Novo Nordisk's witnesses were reliable, Eli Lilly's ads had a negligible market impact between April and July. The judge also said that Novo Nordisk's business remained stable.The judge also said that monetary compensation could help Novo Nordisk if it faces any "nontrivial harm" due to absence of ⁠injunction.Novo Nordisk had reported combined sales of about $32 billion for obesity medicines and Ozempic in 2025, according to the court papers. The drugmaker intends to regain market share in the United States for its injectable obesity drugs, a market that could exceed $100 billion by the end of the decade.According to Reuters, Novo Nordisk said, “While we are disappointed with the court’s decision, today's ruling did not decide the question of whether Lilly's advertising is false and misleading, and this litigation is still ongoing. Everyone deserves clear, accurate and up-to-date information when making decisions about their health.”Denying any wrongdoing, Eli Lilly said it welcomed the court’s decision.Also read: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After ChildbirthWhat Is The Lawsuit About? In July, Danish drugmaker Novo Nordisk had filed a lawsuit against Eli Lilly in the US District Court in New Jersey, alleging the company violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug Zepbound and diabetes treatment Mounjaro, according to media reports.Alleging that Eli Lilly’s ads used outdated comparisons,Novo claims Lilly's advertisements:Compared the highest approved doses of Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic.Omitted data on the newer 7.2 mg dose of Wegovy, which, as per Novo, delivers greater weight loss.Relied on older clinical trial data that no longer reflects current approved dosing.Eli Lilly rejected the allegations, saying its advertisements accurately reflect findings from its SURMOUNT-5 clinical trial. According to the company:The study, completed in 2024, compared 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg doses of Wegovy.Novo's 7.2 mg Wegovy received US FDA approval only in March 2026, after the trial had concluded.   More About GLP-1 TherapiesAlso read: Eli Lilly's Experimental GLP-1 Pill Shows Promising Weight LossIn December 2025, the World Health Organization (WHO) issued its first guideline on the use of GLP-1 therapies for obesity, describing the condition as a chronic, relapsing disease affecting more than 1 billion people worldwide. It recommends GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women. Treatment should be combined with structured lifestyle interventions, including a healthy diet, regular physical activity, and behavioral support to improve outcomes.Dr. Vivek Bindal, Principal Director & Head at Max Institute of Minimal Access, Bariatric & Robotic Surgery, said, “Newer anti-obesity medicines, including GLP-1-based and related therapies, have significantly expanded the options available to patients. They can support meaningful weight loss and improve metabolic health when combined with appropriate nutrition, physical activity and behavioural support.”

eli lilly can continue zepbound ads despite novo nordisk’s claims over weight-loss drug comparisons

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Eli Lilly Can Continue Zepbound Ads Despite Novo Nordisk’s Claims Over Weight-Loss Drug Comparisons

Merck’s Experimental Drug Extends Survival By Nearly 7 Months In Endometrial Cancer Trial

CAR-T Therapy Helps Patients With Rare Autoimmune Disease Walk Again, But Another Trial Reports Death

AstraZeneca Cancer Drug Lowers Death Risk By 42% In Advanced Stomach Cancer Trial

Health Conditions A-Z

Eli Lilly Can Continue Zepbound Ads Despite Novo Nordisk’s Claims Over Weight-Loss Drug Comparisons

Merck’s Experimental Drug Extends Survival By Nearly 7 Months In Endometrial Cancer Trial

Children Who Eat More Ultra-Processed Foods May Have Stronger Brain Responses That Increase Cravings